These data indicate that HSF1 inhibition by KRIBB11 simultaneously targets both key oncogenic drivers, ERBB2 and mutp53, in lapatinib-sensitive and lapatinib-resistant ERBB2-overexpressing breast cancer cells. Here, ERBB2 is linked to breast cancer.